Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
JACC. Case Reports
|
July 28, 2021
Occluded or Not?: A Subtle Electrocardiographic Answer
Anne-Flore Plane, Xavier Valette, Katrien Blanchart, et al.
Leukemia
|
September 19, 2024
Is ibrutinib-related atrial fibrillation dose dependent? Insights from an individual case level analysis of the World Health Organization pharmacovigilance database
Joachim Alexandre, Jonaz Font, Da-Silva Angélique, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
April 24, 2025
Identification of Anticancer Drugs Associated to Cancer Therapy-Related Cardiac Dysfunction: A VigiBase® Disproportionality Analysis
Damien Legallois, Angélique Da Silva, Joachim Alexandre, et al.
JACC. Cardiooncology
|
May 5, 2023
Atrial Fibrillation Incidence Associated With Exposure to Anticancer Drugs Used as Monotherapy in Clinical Trials
Joachim Alexandre, Louis Boismoreau, Pierre-Marie Morice, et al.
European Heart Journal
|
September 16, 2021
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis
Charles Dolladille, Julia Akroun, Pierre-Marie Morice, et al.
Archives of Cardiovascular Diseases
|
May 19, 2020
Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis
Charles Dolladille, Jonaz Font, Theodora Bejan-Angoulvant, et al.
Fundamental & Clinical Pharmacology
|
March 12, 2018
PAR1 contribution in acute electrophysiological properties of oral anticoagulants in rabbit pulmonary vein sleeve preparations
Jonaz Font, Mathilda Simeon, Christophe Simard, et al.
Journal for Immunotherapy of Cancer
|
January 29, 2020
Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
Charles Dolladille, Stephane Ederhy, Stéphane Allouche, et al.
Biomedicines
|
September 27, 2025
Association Between the Renin-Angiotensin System and Ibrutinib-Related Cardiovascular Adverse Events: A Translational Cohort Study
Jonaz Font, Amir Hodzic, Angélique Da-Silva, et al.
JAMA Oncology
|
April 17, 2020
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
Charles Dolladille, Stéphane Ederhy, Marion Sassier, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
JACC. Case Reports
|
July 28, 2021
Occluded or Not?: A Subtle Electrocardiographic Answer
Anne-Flore Plane, Xavier Valette, Katrien Blanchart, et al.
Leukemia
|
September 19, 2024
Is ibrutinib-related atrial fibrillation dose dependent? Insights from an individual case level analysis of the World Health Organization pharmacovigilance database
Joachim Alexandre, Jonaz Font, Da-Silva Angélique, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
April 24, 2025
Identification of Anticancer Drugs Associated to Cancer Therapy-Related Cardiac Dysfunction: A VigiBase® Disproportionality Analysis
Damien Legallois, Angélique Da Silva, Joachim Alexandre, et al.
JACC. Cardiooncology
|
May 5, 2023
Atrial Fibrillation Incidence Associated With Exposure to Anticancer Drugs Used as Monotherapy in Clinical Trials
Joachim Alexandre, Louis Boismoreau, Pierre-Marie Morice, et al.
European Heart Journal
|
September 16, 2021
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis
Charles Dolladille, Julia Akroun, Pierre-Marie Morice, et al.
Archives of Cardiovascular Diseases
|
May 19, 2020
Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis
Charles Dolladille, Jonaz Font, Theodora Bejan-Angoulvant, et al.
Fundamental & Clinical Pharmacology
|
March 12, 2018
PAR1 contribution in acute electrophysiological properties of oral anticoagulants in rabbit pulmonary vein sleeve preparations
Jonaz Font, Mathilda Simeon, Christophe Simard, et al.
Journal for Immunotherapy of Cancer
|
January 29, 2020
Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
Charles Dolladille, Stephane Ederhy, Stéphane Allouche, et al.
Biomedicines
|
September 27, 2025
Association Between the Renin-Angiotensin System and Ibrutinib-Related Cardiovascular Adverse Events: A Translational Cohort Study
Jonaz Font, Amir Hodzic, Angélique Da-Silva, et al.
JAMA Oncology
|
April 17, 2020
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
Charles Dolladille, Stéphane Ederhy, Marion Sassier, et al.
Page
of 2